[Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells].
The guinea-pig basilar artery smooth muscle cell (GBa-SM3) culture system in the Dulbecco's modified Eagle's medium for 3 days serves as a useful in vitro model for assessing antiproliferative effects of various therapeutic agents on vessels. With use of this system we studied whether human serum obtained from patients with acute cerebral infarction (n = 16) would have a proliferative effect on vessels and whether an administration of a free radical scavenger, edaravone, with or without amlodipine would elicit antiproliferative effects. The control serum was obtained from 3 healthy human subjects. Time courses of the cell growth and survival were measured colorimetrically by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrzolium bromide (MTT) test. The stimulatory effect on the proliferation of GBa-SM3 cells of patients' serum obtained immediately after infarction was significantly (p < 0.05) greater than those obtained from the same patients after the treatment of edaravone for 2 weeks. In addition, the serum obtained from the patients treated by edaravone and amlodipine (n = 7) showed a significantly (p < 0.05) greater antiproliferative effect than that obtained from those treated by edaravone (n = 9). In conclusion, edaravone may have a clinically beneficial antiproliferative effect on vascular smooth muscle cells. Co-administration of amlodipine, possessing an antioxidative calcium channel blocker, with edaravone may be a promising combination to patients with acute cerebral infarction. Further controlled clinical trials with a large number of patients should be warranted.
Yamaguchi
Tomoaki
T
Department of Hospital Pharmacy, Nakano General Hospital, 4-59-16 Chuou, Nakano-ku, Tokyo 164-8607, Japan.
Ida
Takashi
T
Kobayashi
Takayoshi
T
Hiraga
Masazumi
M
Oishi
Kazuhiko
K
Uchida
Masaatsu K
MK
Echizen
Hirotoshi
H
D000208:Acute Disease; D000368:Aged; D017311:Amlodipine / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D001488:Basilar Artery / Q000166:cytology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D002544:Cerebral Infarction / Q000097:blood / Q000473:pathology*; D003864:Depression, Chemical; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D044967:Serum / Q000502:physiology*
D000975:Antioxidants; D002121:Calcium Channel Blockers; D016166:Free Radical Scavengers; D017311:Amlodipine; D000077553:Edaravone; D000983:Antipyrine